Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1999 1
2004 2
2005 4
2006 14
2007 15
2008 16
2009 32
2010 57
2011 71
2012 84
2013 97
2014 83
2015 81
2016 78
2017 128
2018 111
2019 92
2020 102
2021 132
2022 125
2023 126
2024 142
2025 84

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,465 results

Results by year

Filters applied: . Clear all
Page 1
The adverse-effect profile of lacosamide.
Li J, Sun M, Wang X. Li J, et al. Expert Opin Drug Saf. 2020 Feb;19(2):131-138. doi: 10.1080/14740338.2020.1713089. Epub 2020 Jan 15. Expert Opin Drug Saf. 2020. PMID: 31914330 Review.
Introduction: Lacosamide has been used in epilepsy patients in the United States, Europe and Asia since it was approved by the FDA in 2008. ...The review showed that lacosamide is safe and effective in antiepileptic treatment, and its common side effects are dizzine …
Introduction: Lacosamide has been used in epilepsy patients in the United States, Europe and Asia since it was approved by the FDA in …
[Paediatric status epilepticus].
Soto-Insuga V, González-Alguacil E, García-Peñas JJ. Soto-Insuga V, et al. Rev Neurol. 2022 Oct 16;75(8):225-238. doi: 10.33588/rn.7508.2022196. Rev Neurol. 2022. PMID: 36218253 Free PMC article. Review. Spanish.
DEVELOPMENT: This article will review the different therapeutic options for status, from early treatment at home to the different first-line (benzodiazepines), second-line (phenobarbital, valproic acid, phenytoin, levetiracetam and lacosamide) or third-line treatments, whi …
DEVELOPMENT: This article will review the different therapeutic options for status, from early treatment at home to the different first-line …
Antiseizure Drugs and Movement Disorders.
Sáenz-Farret M, Tijssen MAJ, Eliashiv D, Fisher RS, Sethi K, Fasano A. Sáenz-Farret M, et al. CNS Drugs. 2022 Aug;36(8):859-876. doi: 10.1007/s40263-022-00937-x. Epub 2022 Jul 21. CNS Drugs. 2022. PMID: 35861924 Review.
Antiseizure drugs mainly used to treat movement disorders are clonazepam, gabapentin, lacosamide, levetiracetam, oxcarbazepine, perampanel, phenobarbital, pregabalin, primidone, topiramate, and zonisamide. ...Antiseizure drugs with a variable effect on movement disorders a …
Antiseizure drugs mainly used to treat movement disorders are clonazepam, gabapentin, lacosamide, levetiracetam, oxcarbazepine, peram …
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Strzelczyk A, Schubert-Bast S. Strzelczyk A, et al. CNS Drugs. 2022 Oct;36(10):1079-1111. doi: 10.1007/s40263-022-00955-9. Epub 2022 Oct 4. CNS Drugs. 2022. PMID: 36194365 Free PMC article. Review.
The ASMs include valproate (VPA), clobazam, topiramate (TPM), cannabidiol (CBD), fenfluramine (FFA), levetiracetam (LEV), brivaracetam (BRV), zonisamide (ZNS), perampanel (PER), ethosuximide, stiripentol, lamotrigine (LTG), rufinamide, vigabatrin, lacosamide (LCM) and ever …
The ASMs include valproate (VPA), clobazam, topiramate (TPM), cannabidiol (CBD), fenfluramine (FFA), levetiracetam (LEV), brivaracetam (BRV) …
Lacosamide in status epilepticus: Systematic review of current evidence.
Strzelczyk A, Zöllner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, Rosenow F, Bauer S. Strzelczyk A, et al. Epilepsia. 2017 Jun;58(6):933-950. doi: 10.1111/epi.13716. Epub 2017 Mar 11. Epilepsia. 2017. PMID: 28295226 Review.
OBJECTIVE: The intravenous formulation of lacosamide (LCM) and its good overall tolerability and safety favor the use in status epilepticus (SE). ...The main adverse events during treatment of SE are dizziness, abnormal vision, diplopia, and ataxia. Overall, lacosamide …
OBJECTIVE: The intravenous formulation of lacosamide (LCM) and its good overall tolerability and safety favor the use in status epile …
Lacosamide and pregnancy: Data from spontaneous and solicited reports.
Perucca P, Bourikas D, Voinescu PE, Vadlamudi L, Chellun D, Kumke T, Werhahn KJ, Schmitz B. Perucca P, et al. Epilepsia. 2024 May;65(5):1275-1284. doi: 10.1111/epi.17924. Epub 2024 Feb 27. Epilepsia. 2024. PMID: 38411300
Data are limited on pregnancy outcomes among patients taking lacosamide (LCM), particularly when taken as monotherapy. The objective of this analysis was to evaluate the pregnancy outcomes of LCM-exposed pregnancies. ...
Data are limited on pregnancy outcomes among patients taking lacosamide (LCM), particularly when taken as monotherapy. The objective …
Lacosamide.
Doty P, Rudd GD, Stoehr T, Thomas D. Doty P, et al. Neurotherapeutics. 2007 Jan;4(1):145-8. doi: 10.1016/j.nurt.2006.10.002. Neurotherapeutics. 2007. PMID: 17199030 Free PMC article. Review.
In addition, 50% responder rates for lacosamide (400 and 600 mg/day) were statistically superior to placebo. The most frequently reported adverse events (> or =10% of lacosamide-treated patients) included dizziness, headache, and nausea. A double-blind, double-du …
In addition, 50% responder rates for lacosamide (400 and 600 mg/day) were statistically superior to placebo. The most frequently repo …
Lacosamide.
Perucca E, Yasothan U, Clincke G, Kirkpatrick P. Perucca E, et al. Nat Rev Drug Discov. 2008 Dec;7(12):973-4. doi: 10.1038/nrd2764. Nat Rev Drug Discov. 2008. PMID: 19043448
In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. ...
In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for pa …
Structural mapping of Nav1.7 antagonists.
Wu Q, Huang J, Fan X, Wang K, Jin X, Huang G, Li J, Pan X, Yan N. Wu Q, et al. Nat Commun. 2023 Jun 3;14(1):3224. doi: 10.1038/s41467-023-38942-3. Nat Commun. 2023. PMID: 37270609 Free PMC article.
A binding site beneath the intracellular gate (site BIG) accommodates carbamazepine, bupivacaine, and lacosamide. Unexpectedly, a second molecule of lacosamide plugs into the selectivity filter from the central cavity. ...
A binding site beneath the intracellular gate (site BIG) accommodates carbamazepine, bupivacaine, and lacosamide. Unexpectedly, a sec …
Lacosamide-induced rash.
Koubeissi MZ, Vismer M, Ehrlich A. Koubeissi MZ, et al. Epileptic Disord. 2014 Sep;16(3):380-3. doi: 10.1684/epd.2014.0667. Epileptic Disord. 2014. PMID: 25035958 Free article.
However, these side-effects have rarely been previously reported for lacosamide, a newer-generation anti-seizure medication with a novel mechanism of action. Here, we report a case of diffuse skin eruption in a patient with history of epilepsy soon after initiation of l …
However, these side-effects have rarely been previously reported for lacosamide, a newer-generation anti-seizure medication with a no …
1,465 results